Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ipsen Pharmaceuticals
Biotech
Ipsen pens €700M deal to buy Swiss biotech for rare disease drug
Ipsen is on a roll this week, scooping up its second biotech in three days to firm up its pipeline with promising clinical-stage candidates.
James Waldron
Jul 1, 2026 8:05am
Ipsen inks $1.7B deal to buy Kartos for potential Jakafi add-on
Jun 29, 2026 8:03am
BioNTech founders to pioneer new company—Chutes & Ladders
Mar 13, 2026 8:30am
Ipsen's ADC push leads to $1B deal for preclinical Simcere drug
Dec 22, 2025 7:15am
Ipsen fails to land pivotal rare disease trial
Dec 19, 2025 3:37pm
Ipsen inks €1B buyout of French biotech ImCheck
Oct 22, 2025 10:33am
